Giovanni Armenise - Harvard Professor of Neurology, Harvard Medical School; Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Co-Leader, Brain Cancer Program, Dana-Farber Harvard Cancer Ce
Neurology
Dr. Tracy T. Batchelor, MD
|
|
Give Review
Tracy T. Batchelor, MD works in the field of Neurology. He researched medicine at Emory University School of Medicine. Emory University School of Medicine is ranked 23/42 in Research/PrimaryCare. He over the years received 4 awards: "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer" and "Super Doctor". Tracy Batchelor is also published. He has 100 publications published. The lastest publication: "Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional Spectroscopic Mapping of 2-Hydroxyglutarate.
- Management of patients with recurrence of diffuse low grade glioma : A Systematic review and evidence-based clinical practice guideline.
- Neurocognitive effects of proton radiation therapy in adults with low-grade glioma.
- Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma.
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Proton therapy for low-grade Gliomas: Results from a prospective trial.
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
- Brain tumor cells in circulation are enriched for mesenchymal gene expression.
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
- Vessel calibre-a potential MRI biomarker of tumour response in clinical trials.
- Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transpl...
- Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant Gliomas.
- Comment: Defining cure in primary CNS Lymphoma.
- Impact of MRI head placement on glioma response assessment.
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
- Primary leptomeningeal Lymphoma: International Primary CNS Lymphoma Collaborative Group report.
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Gli...
- Vessel architectural imaging identifies Cancer patient responders to anti-angiogenic therapy.
- Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
- Recent Advances in Treatment of Primary Central Nervous System Lymphoma.
- Plasmablastic Lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
- Flying Solo: Chemotherapy Without Radiation for Primary CNS Lymphoma.
- BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults.
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS Lymphoma.
- Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
- Primary central Nervous system lymphoma: overview of current treatment strategies.
- Prospective, high-throughput molecular profiling of human Gliomas.
- Case records of the Massachusetts General Hospital. Case 17-2012. A 54-year-old man with visual-field loss and a mass in the Brain.
- Response to C. Massard et al.
- Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor.
- Increased Survival of Glioblastoma Patients who Respond to Anti-angiogenic Therapy with Elevated Blood Perfusion.
- Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (tbc) conditioning in patients with cns involvement by non-hodgkin Lymphoma.
- T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: Part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
- Serial MR Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma.
- Exacerbation of Cerebral radiation necrosis by bevacizumab.
- Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
- BRAF V600E Mutations Are Common in Pleomorphic XanthoAstrocytoma: Diagnostic and Therapeutic Implications.
- Imaging and response criteria in Gliomas.
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard...
- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
- Erlotinib for progressive vestibular Schwannoma in neurofibromatosis 2 patients.
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
- Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
- Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
- VEGF inhibitors in Brain tumors.
- Prospective study of meat intake and dietary nitrates, nitrites, and nitrosamines and risk of adult glioma.
- A "vascular Normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
- Angiogenesis as a therapeutic target in malignant Gliomas.
- Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent Brain tumor growth in mice.
- Anti-vascular endothelial growth factor therapy for malignant glioma.
- Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q.
- High-dose methotrexate for elderly patients with primary CNS Lymphoma.
- VEGF inhibitors in the treatment of cerebral edema in patients with Brain cancer.
- Insights into the biology of primary central Nervous system lymphoma.
- A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
- Differential gene expression in central Nervous system lymphoma.
- CNS Hodgkin Lymphoma.
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
- Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation.
- MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
- Phase II study of metronomic chemotherapy for recurrent malignant Gliomas in adults.
- Leptomeningeal neoplasms.
- Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.
- Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, Normalizes tumor vasculature and alleviates edema in glioblastoma patients.
- Supportive care of Brain tumor patients.
- Activation of STAT3, MAPK, and AKT in malignant astrocytic Gliomas: correlation with EGFR status, tumor grade, and survival.
- The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
- International study on low-grade primary central Nervous system lymphoma.
- A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant Gliomas after alkylator chemotherapy.
- Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade Gliomas.
- Primary central Nervous system lymphoma: presentation, diagnosis and staging.
- Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
- Genetic analyses for predictors of radiation response in glioblastoma.
- Statistical considerations for immunohistochemistry panel development after gene expression profiling of human Cancers.
- YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade Gliomas.
- Results of whole-Brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, Headache, and nausea.
- Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoAstrocytoma: case study.
- Treatment of relapsed central Nervous system lymphoma with high-dose methotrexate.
- Age-dependent prognostic effects of genetic alterations in glioblastoma.
- Malignant Peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment.
- Gene expression-based classification of malignant Gliomas correlates better with survival than histological classification.
- BCL-6 expression predicts improved survival in patients with primary central Nervous system lymphoma.
- Leptomeningeal metastases.
- High-dose methotrexate for intraocular Lymphoma.
- Primary Nervous system lymphoma.
- Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners.
- Antiangiogenic Therapy for Glioblastoma.
- Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.
- Low-grade Gliomas.
Schools
Emory University
YaleNew Haven Hospital
Massachusetts General Hospital
Sloan Kettering Cancer Center
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Ataxia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Super Doctor
Education
-
Massachusetts General Hospital -
Yale New Haven Children's Center -
Emory University School of Medicine
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1952391260 | |
| NPPES Provider LastName | BATCHELOR | |
| NPPES Provider FirstName | TRACY | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 83.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952391260 |
| Last Name Of The Provider | BATCHELOR |
| First Name Of The Provider | TRACY |
| View All |
Similar Doctors
|
|
Dr. Joshua D. Katz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David N. Caplan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Shruti P. Agnihotri, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shawn N. Murphy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Holtzman, MD |
|
|
Dr. Martha R. Neagu, MD |
|
|
Dr. Laverne D. Gugino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. McGinnis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Ronthal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven C. Schachter, MD
This Doctor is OpenDoctor Recommended.
|